PCRX
Pacira BioSciences, Inc.
NASDAQ · Healthcare · Drug Manufacturers - Specialty & Generic · US
$26.35
−0.94%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 746.2M | 726.4M | 701.0M | 675.0M | 666.8M |
| Cost of Revenue | 155.2M | 149.7M | 170.4M | 184.7M | 199.3M |
| Gross Profit | 591.0M | 576.7M | 530.5M | 490.3M | 467.5M |
| Operating Expenses | |||||
| R&D Expense | 121.7M | 117.3M | 81.6M | 76.3M | 84.8M |
| SG&A Expense | 379.2M | 368.8M | 294.1M | 269.4M | 254.5M |
| General & Admin Expense | 200.9M | 142.1M | 122.1M | 116.4M | 109.5M |
| Selling & Marketing Expense | 178.2M | 226.6M | 172.0M | 153.0M | 145.0M |
| Other Expenses | 71.7M | 57.3M | 228.2M | 56.9M | 68.2M |
| Total Operating Expenses | 572.6M | 543.4M | 603.9M | 402.6M | 407.5M |
| Cost and Expenses | 727.7M | 693.1M | 774.3M | 587.3M | 606.8M |
| Operating Income (EBIT) | 18.4M | 33.3M | (73.4M) | 87.7M | 60.0M |
| Non-Operating | |||||
| Interest Income | 14.7M | 22.7M | 19.7M | 11.4M | 4.5M |
| Interest Expense | 13.8M | 14.6M | 16.6M | 17.3M | 35.6M |
| Net Interest Income | 878.0K | 8.1M | 3.1M | (5.9M) | (31.0M) |
| Other Non-Op Income/Expense | (797.0K) | (16.4M) | 10.3M | (26.0M) | (46.7M) |
| Non-Operating Income (excl Interest) | (11.2M) | 1.8M | (23.7M) | 8.7M | 11.1M |
| EBT (Pre-Tax Income) | 17.6M | 16.9M | (63.1M) | 61.7M | 13.3M |
| Income Tax Expense | 3.0M | 9.8M | 36.5M | 19.7M | (2.6M) |
| Bottom Line | |||||
| Net Income | 14.6M | 7.0M | (99.6M) | 42.0M | 15.9M |
| Earnings from Cont. Ops | 14.6M | 7.0M | (99.6M) | 42.0M | 15.9M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 14.6M | 7.0M | (99.6M) | 46.1M | 15.9M |
| Per Share | |||||
| Basic EPS | $0.35 | $0.16 | ($2.15) | $0.91 | $0.35 |
| Diluted EPS | $0.35 | $0.16 | ($2.15) | $0.89 | $0.34 |
| Revenue Per Share | $18.91 | $16.30 | $15.16 | $14.60 | $14.65 |
| Shares | |||||
| Basic Shares Outstanding | 39.5M | 44.6M | 46.2M | 46.2M | 45.5M |
| Diluted Shares Outstanding | 40.3M | 45.0M | 46.2M | 52.0M | 46.5M |
| Profitability Metrics | |||||
| EBITDA | 114.8M | 122.5M | 29.1M | 154.6M | 140.4M |
| D&A | 85.2M | 91.0M | 78.8M | 75.6M | 91.5M |
| EBIT | 29.6M | 31.5M | (49.7M) | 79.0M | 48.9M |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Jun 1, 2026